Patents by Inventor Craig B. Thompson
Craig B. Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7144575Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: March 17, 2003Date of Patent: December 5, 2006Assignees: The Regents of the University of Michigan, Genetics Institute, LLC, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 7067318Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.Type: GrantFiled: September 9, 2003Date of Patent: June 27, 2006Assignees: The Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Suil Kim
-
Patent number: 6911532Abstract: The invention relates generally to compositions of and methods for obtaining and using a polypeptide other than BCL-2 that affects programmed vertebrate cell death. The invention relates as well to polynucleotides encoding those polypeptides, recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant polypeptides. The invention further provides methods for using the isolated, recombinant polypeptides in assays designed to select and improve substances capable of altering programmed cell death for use in diagnostic, drug design and therapeutic applications.Type: GrantFiled: September 12, 2001Date of Patent: June 28, 2005Assignee: The Reagents of the University of MichiganInventors: Craig B. Thompson, Lawrence H. Boise, Gabriel Nuñez
-
Patent number: 6905680Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: January 26, 1996Date of Patent: June 14, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6905681Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: July 8, 1999Date of Patent: June 14, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6887466Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: July 8, 1999Date of Patent: May 3, 2005Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Publication number: 20040203155Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.Type: ApplicationFiled: April 20, 2004Publication date: October 14, 2004Applicants: The United States of America as Represented by the Secretary of the Navy, The Regents of the University of MichiganInventors: Carl H. June, Craig B. Thompson, Suil Kim
-
Publication number: 20040185046Abstract: The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.Type: ApplicationFiled: November 14, 2003Publication date: September 23, 2004Inventors: Craig B. Thompson, Carl H. June
-
Publication number: 20040087025Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.Type: ApplicationFiled: September 9, 2003Publication date: May 6, 2004Applicants: The United States of America as Represented by the Secretary of the Navy, The Regents of the University of MichiganInventors: Carl H. June, Craig B. Thompson, Suil Kim
-
Patent number: 6692964Abstract: A method for transfecting T cells with a nucleic acid molecule comprising a gene such that the gene is expressed in the T cells is described. The T cells are stimulated and proliferating prior to introduction of the nucleic acid molecule.Type: GrantFiled: June 7, 1995Date of Patent: February 17, 2004Assignees: The United States of America as represented by the Secretary of the Navy, The Regents of the University of MichiganInventors: Carl H. June, Craig B. Thompson, Suil Kim
-
Patent number: 6685941Abstract: The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.Type: GrantFiled: February 7, 1995Date of Patent: February 3, 2004Assignees: The Regents of the University of Michigan, The United States of America as represented by the Secretary of the NavyInventors: Craig B. Thompson, Carl H. June
-
Publication number: 20040001829Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: ApplicationFiled: March 17, 2003Publication date: January 1, 2004Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Publication number: 20030157102Abstract: A method of immunotherapy stimulates the T cell CD28 surface molecule to enhance T cell proliferation and increase overall lymphokine levels or to increase cellular production of human TH1 lymphokines or both. The method is selective for the induction of activated T cell mediated immune responses and enhances immune function even in the presence of immunosuppresants.Type: ApplicationFiled: March 13, 2002Publication date: August 21, 2003Applicant: The Regents of the University of MichiganInventors: Craig B. Thompson, Carl H. June, Jeffrey A. Ledbetter, Tullia Lindsten
-
Publication number: 20030099643Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: ApplicationFiled: July 8, 1999Publication date: May 29, 2003Inventors: CARL H. JUNE, CRAIG B. THOMPSON, GARY J. NABEL, GARY S. GRAY, PAUL D. RENNERT
-
Publication number: 20030091982Abstract: The present invention relates to a composition comprising an immortalized cell line which is deficient in the expression of one or more gene(s) of the intrinsic apoptotic pathway, selected from the group consisting of Bax, Bak, and mixtures thereof. The present invention further relates to the product of a process for producing an immortalized mouse fibroblast cell line which is deficient in the expression of Bax, Bak, and mixtures thereof. Finally, the present invention relates to a method and a kit for identifying a compound or composition which induces or blocks the extrinsic apoptotic pathway.Type: ApplicationFiled: November 12, 2002Publication date: May 15, 2003Inventors: Wei-Xing Zong, Craig B. Thompson, Tullia Lindsten
-
Patent number: 6534055Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: GrantFiled: May 4, 1995Date of Patent: March 18, 2003Assignee: Genetics Institute, Inc.Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
-
Patent number: 6511828Abstract: A new family of proteins having structural similarity to the baculovirus inhibitor of apoptosis protein (iap) are described. These ilp's (iap-like proteins) are distinguished by the presence of a RING finger domain and three baculovirus iap-like repeat motifs. Exemplified are sequences from Drosophila and human. Methods for the use of these proteins, and nucleic acids coding therefor, are provided. These methods include both the inhibition and stimulation of apoptosis in target cells.Type: GrantFiled: May 31, 1996Date of Patent: January 28, 2003Assignee: Arch Development CorporationInventors: Craig B. Thompson, Colin S. Duckett
-
Publication number: 20020137182Abstract: The invention relates generally to compositions of and methods for obtaining and using a polypeptide other than BCL-2 that affects programmed vertebrate cell death. The invention relates as well to polynucleotides encoding those polypeptides, recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant polypeptides. The invention further provides methods for using the isolated, recombinant polypeptides in assays designed to select and improve substances capable of altering programmed cell death for use in diagnostic, drug design and therapeutic applications.Type: ApplicationFiled: September 12, 2001Publication date: September 26, 2002Applicant: The Regent of the University of MichiganInventors: Craig B. Thompson, Lawrence H. Boise, Gabriel Nunez
-
Publication number: 20020115214Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: ApplicationFiled: January 26, 1996Publication date: August 22, 2002Inventors: CARL H. JUNE, CRAIG B. THOMPSON, GARY J. NABEL, GARY S. GRAY, PAUL D. RENNERT
-
Publication number: 20020076407Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.Type: ApplicationFiled: October 29, 1998Publication date: June 20, 2002Inventors: CARL H. JUNE, CRAIG B. THOMPSON, GARY J. NABEL, GARY S. GRAY, PAUL D. RENNERT, GORDON J. FREEMAN